1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | |
| brand | String | Belsomra |
| structure | File | |
| classes | List of String, delimiter: , | Dual orexin receptor antagonist (DORA) • the first approved |
| mechanism | String | Competitive antagonist at OX1R and OX2R. First-in-class DORA. Receptor dissociation slower than lemborexant or daridorexant. |
| uses | String | Insomnia (sleep onset and/or maintenance) in adults (FDA-approved August 2014). Also studied for insomnia in mild-moderate Alzheimer disease. |
| starting_dose | String | 10 mg PO 30 min before bedtime (with ≥7 hours of sleep planned) |
| preparations | String | 5 mg, 10 mg, 15 mg, 20 mg tablets |
| fda_max | String | 20 mg/d |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral |
| onset | String | ~30 min |
| duration | String | ~7-8 hours |
| halflife | String | ~12 hours |
| bioavailability | String | ~82% |
| pregnancy | String | Limited data; avoid |
| legal | String | Rx, Schedule IV (US) |
